Success Story: Decoding Protein Interactions for Better Disease Research: EB1A Approved for a Chinese Postdoctoral Associate Advancing Proteomics Methods
Client’s Testimonial:
"I am extremely excited to receive the approval notice—this is such great news. Thank you very much for your excellent work and support throughout the EB-1A process."
On February 5th, 2026, we received another EB1A (Alien of Extraordinary Ability) approval for a Postdoctoral Associate in the field of Network Cell and Molecular Biology (Approval Notice).
General Field: Network Cell and Molecular Biology
Position at the Time of Case Filing: Postdoctoral Associate
Country of Origin: China
State of Residence at the Time of Filing: New York
Approval Notice Date: February 5th, 2026
Processing Time: 16 days (Premium Processing Requested)
Case Summary:
Some of the most important questions in biology are questions of networks: which proteins interact, where those interactions occur inside the cell, and how they shift in disease. In this petition, we presented a Chinese postdoctoral associate whose work develops and applies advanced proteomics approaches to map protein interactions and native complexes at scale, combining computational analysis with experimental systems biology. At the time of filing, the client was continuing this work in the United States in a postdoctoral research role aligned with large-scale proteomic and molecular network analysis.
Extraordinary Research Contributions
The petition emphasized original contributions of major significance that expand what researchers can measure in complex biological systems. Specifically, the client’s work strengthened tools for analyzing native protein complexes in structural detail and advanced methods for capturing subcellular protein interaction information that is difficult to observe with conventional techniques. We also described how these capabilities support progress in understanding chromatin and transcription-related biology and can accelerate downstream discovery relevant to disease mechanisms and therapeutic development.
Academic Record and Recognition
The petition documented a strong record of authorship and independent influence. The client has authored 10 peer-reviewed journal articles, 2 preprints, and holds 3 patents. This body of work has received 561 citations, reflecting meaningful reliance by other researchers. The petition also documented at least 44 completed peer reviews for respected journals, showing repeated professional trust in the client’s technical judgment as an evaluator. Together, these indicators helped show that the client’s expertise is recognized by both researchers who cite the work and editors who rely on the client’s review service.
Expert Endorsements
The filing included expert letters, including multiple independent advisory opinions, explaining why the client’s proteomics contributions are influential beyond any single lab and how other researchers rely on these methods and findings.
One expert summarized the broader value of this work as follows:
“Given the significant burden cancer places on national and international healthcare systems, [Client]'s work in describing protein interactions is critical to clinical research.”
This assessment aligned with the petition’s framing that improving protein-interaction mapping methods helps enable higher-confidence biomedical research directions, including disease-focused studies that depend on reliable molecular network evidence.EB1A Approval and Outlook
The I-140 EB1A petition was filed on January 20th, 2026, and approved on February 5th, 2026, under premium processing. In the filing, we demonstrated extraordinary ability through evidence of original contributions of major significance, influential scholarly authorship, strong citation impact, and repeated trust as a peer reviewer. With this approval, the client is well-positioned to continue advancing proteomics-enabled research that strengthens how scientists map protein interaction networks and study complex cellular mechanisms relevant to human disease.